We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

99 hedge funds and large institutions have $690M invested in Heron Therapeutics in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $21.1M | Put options by funds: $8.42M

134.39% more ownership

Funds ownership: 0% → 134.39% (+134%)

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

13% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 30

9% more funds holding

Funds holding: 91 → 99 (+8)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

22% less capital invested

Capital invested by funds: $881M → $690M (-$191M)

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
2.48%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
18
Increased
34
Reduced
30
Closed
10
Calls
$21.1M
Puts
$8.42M
Net Calls
+$12.7M
Net Calls Change
+$7.51M

Top Buyers

1
BC
Broadfin Capital
New York
+$16.5M
2
HCMT
Highland Capital Management (Texas)
Texas
+$14.3M
3
JHIU
Janus Henderson Investors US
Colorado
+$8.5M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$5.13M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.04M

Top Sellers

1
Invesco
Invesco
Georgia
-$34.3M
2
PHS
PFM Health Sciences
California
-$10.3M
3
BBA
Baker Bros. Advisors
New York
-$7.43M
4
RI
RTW Investments
New York
-$6.66M
5
Asset Management One
Asset Management One
Japan
-$4.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
BGIM
51
Brandywine Global Investment Management
Pennsylvania
$530K -$293K -18,662 -32%
Squarepoint
52
Squarepoint
New York
$478K +$351K +22,367 +159%
New York State Common Retirement Fund
53
New York State Common Retirement Fund
New York
$459K – – –
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$453K -$13.5K -863 -2%
CS
55
Credit Suisse
Switzerland
$439K -$212K -13,518 -29%
VKH
56
Virtu KCG Holdings
New York
$396K +$475K +30,262 New
Goldman Sachs
57
Goldman Sachs
New York
$355K -$168K -10,703 -28%
TI
58
Trexquant Investment
Connecticut
$353K +$422K +26,915 New
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$341K – – –
Wells Fargo
60
Wells Fargo
California
$290K +$172K +10,970 +98%
Manulife (Manufacturers Life Insurance)
61
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$282K +$6.92K +441 +2%
NFA
62
Nationwide Fund Advisors
Ohio
$259K -$15.5K -991 -5%
AIG
63
American International Group
New York
$239K -$753 -48 -0.3%
PPA
64
Parametric Portfolio Associates
Washington
$232K -$48.7K -3,102 -15%
State Board of Administration of Florida Retirement System
65
State Board of Administration of Florida Retirement System
Florida
$221K – – –
BA
66
BlackRock Advisors
Delaware
$217K -$10.7K -683 -4%
HCM
67
Highbridge Capital Management
New York
$206K +$3.95K +252 +2%
HighTower Advisors
68
HighTower Advisors
Illinois
$196K -$115K -7,300 -33%
D.E. Shaw & Co
69
D.E. Shaw & Co
New York
$185K +$222K +14,120 New
VOYA Investment Management
70
VOYA Investment Management
Georgia
$173K – – –
BG
71
BlackRock Group
United Kingdom
$164K +$19.4K +1,237 +11%
Barclays
72
Barclays
United Kingdom
$162K +$184K +11,715 +1,880%
Bank of Montreal
73
Bank of Montreal
Ontario, Canada
$160K -$16K -1,020 -9%
NIT
74
NumerixS Investment Technologies
British Columbia, Canada
$155K +$185K +11,800 New
Legal & General Group
75
Legal & General Group
United Kingdom
$102K +$62.8K +4,000 +103%
1 2
3
4 5

HRTX Hedge Fund Activity: Q4 2016 in Review

99 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2016, worth a combined $690M — down 22% from $881M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new HRTX positions and 10 closed out — a net gain of 8 holders — while 34 added to existing stakes and 30 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $16.5M. The largest seller was Invesco, cutting an estimated $34.3M.

  • 99 institutional investors held Heron Therapeutics (HRTX) as of Q4 2016, up from 91 in Q3 2016.
  • Funds reported $690M of Heron Therapeutics stock for Q4 2016, down 22% quarter-over-quarter.
  • 18 funds opened new Heron Therapeutics positions in Q4 2016 and 10 closed out, a net change of +8 holders.
  • The largest Heron Therapeutics buyer in Q4 2016 was Broadfin Capital, an estimated $16.5M added.
  • The largest Heron Therapeutics seller in Q4 2016 was Invesco, an estimated $34.3M sold.

Based on aggregated 13F filings for Q4 2016.